Maxion Therapeutics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
The Works suite 4 London Rd, Cambridge, ...Website
www.maxiontherapeutics.comRevenue
$8.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Maxion Therapeutics
Based in Cambridge, England, Maxion Therapeutics is a biotechnology company with a focus on antibodies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Maxion Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Maxion Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Maxion Therapeutics launches new products
Check if Maxion Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Maxion Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Maxion Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Maxion Therapeutics has new funding data
Maxion Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Maxion Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Maxion Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Maxion Therapeutics
Compare insights from companies similar to Maxion Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Maxion Therapeutics
$8.9M
11-50
Private
$88M
2020
N/A
Company Profile Activity
Activity Insights
Maxion Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Maxion Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Maxion Therapeutics.
Maxion Therapeutics financials insights
Gather financial insights about Maxion Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$16M
2025
Series A
$72M
Maxion Therapeutics Tech Stack
A closer look at the technologies used by Maxion Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Open Position
Open Position
New Hire
Executive Move
Executive Moves, New Hire
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Maxion Therapeutics News & Media
Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive Director
Cambridge, UK, 27 August 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, today announces the appointment of Santiago Arroyo, PhD as a Non-Executive Director.Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer
Cambridge, UK, 17 June 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, today announces the appointment of Dr. Stefan Härtle as Chief Development Officer, effective immediately.Maxion Therapeutics Raises $72M in Series A Funding
Maxion Therapeutics, a Cambridge, UK-based biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, raised $72M (£58M) in Series A funding. The round was led by General Catalyst with participation from new investors British Patient Capital, Solasta Ventures and Eli Lilly and Company and existing investors LifeArc Ventures, […] The post Maxion Therapeutics Raises $72M in Series A Funding appeared first on FinSMEs.Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO
CAMBRIDGE, England, Feb. 1, 2024 /PRNewswire/ -- Maxion Therapeutics ("Maxion"), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced today that Dr Arndt Schottelius has been appointed as the new Chief...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Maxion Therapeutics
Sign Up For FreeTo access detailed company insights
Based in Cambridge, England, Maxion Therapeutics is a biotechnology company with a focus on antibodies.... Read More
